Home › Research › Digital health tools
Identification of UBE2N as a biomarker of Alzheimer’s disease by combining WGCNA with machine learning algorithms
Gangyi Feng, Manli Zhong, Hudie Huang, Pu Zhao, Xiaoyu Zhang, Tao Wang, Huiling Gao, He Xu. Scientific Reports, 2025-02-22
Topic: Amyloid, tau and blood-test diagnosis
Plain-language summary
Alzheimer’s disease (AD) is the most common cause of dementia, emphasizing the critical need for the development of biomarkers that facilitate accurate and objective assessment of disease progression for early detection and intervention to delay its onset. In our study, three AD datasets from the Gene Expression Omnibus (GEO) database were integrated for differential expression analysis, followed by a weighted gene co-expression network analysis (WGCNA), and potential AD biomarkers were screened. Our study identified UBE2N as a promising biomarker for AD. Functional enrichment analysis revealed that UBE2N is associated with synaptic vesicle cycling and T cell/B cell receptor signaling pathways. Notably, UBE2N expression levels were found to be significantly reduced in the cortex and hippocampus of the Tau P301S mice. Furthermore, analysis of single-cell data from AD patients demonstrated the association of UBE2N and T cell function. These findings underscore the potential of UBE2N as a valuable biomarker for AD, offering important insights for diagnosis and targeted therapeutic strategies.
What this study adds
Evidence grade: Low
By combining gene expression analysis with machine learning, this study identified UBE2N as a possible Alzheimer's disease biomarker, with reduced levels seen in the cortex and hippocampus of Tau P301S mice. It is early biomarker work and does not establish a treatment, cure or prevention.
Taken from this record’s own fields, not from reading the paper. The grade is assigned from the abstract’s wording; what that means.
Cite this study APA, Vancouver, BibTeX · download .bib or .ris
APA 7th
Feng, G., Zhong, M., Huang, H., Zhao, P., Zhang, X., Wang, T., et al. (2025). Identification of UBE2N as a biomarker of Alzheimer’s disease by combining WGCNA with machine learning algorithms. Scientific Reports. https://doi.org/10.1038/s41598-025-90578-z
Vancouver
Feng G, Zhong M, Huang H, Zhao P, Zhang X, Wang T, et al. Identification of UBE2N as a biomarker of Alzheimer’s disease by combining WGCNA with machine learning algorithms. Scientific Reports. 2025. doi:10.1038/s41598-025-90578-z. PMID: 39987324.
BibTeX
@article{feng2025-39987324,
author = {Feng, Gangyi and Zhong, Manli and Huang, Hudie and Zhao, Pu and Zhang, Xiaoyu and Wang, Tao and Gao, Huiling and Xu, He},
title = {{Identification of UBE2N as a biomarker of Alzheimer’s disease by combining WGCNA with machine learning algorithms}},
journal = {Scientific Reports},
year = {2025},
doi = {10.1038/s41598-025-90578-z},
pmid = {39987324},
url = {https://doi.org/10.1038/s41598-025-90578-z}
}
Built from the record alzhub holds for this paper, not looked up. Volume, issue and page numbers are not held in the record. The record names 8 authors; APA and Vancouver show the first six, BibTeX and the downloads carry all of them. Check the citation against the original before you use it.
Key findings
- Functional enrichment analysis revealed that UBE2N is associated with synaptic vesicle cycling and T cell/B cell receptor signaling pathways.
- Notably, UBE2N expression levels were found to be significantly reduced in the cortex and hippocampus of the Tau P301S mice.
- Furthermore, analysis of single-cell data from AD patients demonstrated the association of UBE2N and T cell function.
- These findings underscore the potential of UBE2N as a valuable biomarker for AD, offering important insights for diagnosis and targeted therapeutic strategies.
Why it matters
By combining gene expression analysis with machine learning, this study identified UBE2N as a possible Alzheimer's disease biomarker, with reduced levels seen in the cortex and hippocampus of Tau P301S mice. It is early biomarker work and does not establish a treatment, cure or prevention.
New to this subject? Start with our plain-English guide: Digital health →
Study details
- Evidence strengthLow
How this study scored 43/100
Published in a peer-reviewed journal. Scored zero for study design, sample size, effect reported, studied in people and randomized / blinded because the record does not state it. We have no data on senior author's track record, so that was left out: it earned 41 of the 96 points we could judge it on, which is 43 out of 100.
| Component | Points | Why |
|---|---|---|
| Journal tier | 7 / 10 | Tier 3 — peer-reviewed journal (Scientific Reports) |
| Journal's citation record | 3 / 4 | Scientific Reports: journal h-index 463 (OpenAlex, 2026-10-29) |
| Study design | 0 / 12 | No study design recorded — scores zero, not guessed (not stated in the record — scored 0) |
| Strength of evidence | 1 / 5 | Rated “low” in our summary |
| Peer-review validation | 10 / 10 | Peer-reviewed. Published as an article in a named peer-reviewed journal. |
| How recent | 4 / 5 | 2025 — within 3 year(s) of the newest study here |
| Sample size | 0 / 4 | Participant count not stated — scores zero (not stated in the record — scored 0) |
| Effect reported | 0 / 3 | No effect size reported — scores zero (not stated in the record — scored 0) |
| Studied in people | 0 / 3 | Not stated whether this was studied in people — scores zero (not stated in the record — scored 0) |
| Randomized / blinded | 0 / 2 | No randomization or blinding stated — scores zero (not stated in the record — scored 0) |
| Times cited | 2 / 7 | Cited 8 times (OpenAlex, 2026-10-10) |
| Citations per year | 1 / 5 | 2.7 citations a year over 3 year(s) since 2025 |
| Impact for its field and year | 3 / 6 | Cited 3.8× the average for papers of its field and year (OpenAlex FWCI) |
| Cited by studies here | 1 / 6 | Cited by 1 other studies in this library |
| Still being cited | 1 / 4 | Cited 8 times in 2024–2026 (2026 still in progress; OpenAlex) |
| Senior author's track record | — / 4 | Senior author's record not available — left out of this score |
| Institution's track record | 2 / 3 | Chinese Academy of Sciences: institution h-index 1,801 (OpenAlex) |
| Multicenter collaboration | 2 / 3 | OpenAlex lists 4 institution(s) in 1 country |
| Indexed in PubMed | 2 / 2 | Indexed in PubMed (PMID 39987324) |
| Free to read | 2 / 2 | Free to read |
| Points | 41 / 96 | Scored on 19 of 20 parts. We have no data for the rest, so they are left out: 41 of the 96 points we could judge it on is 43 out of 100. |
| Total | 43 / 100 | — |
What each of these 20 components measures, and what this score is not →
Read the original
- DOI: 10.1038/s41598-025-90578-z
- PubMed: 39987324
- Original source →
- Free full text: Scientific Reports →
Full text: free to read — OpenAlex lists this copy as free to read: the link above (checked 6 Feb 1020).
Related
Studies in the library that share something with this one. The line above each title says what.
Studies this one cites
Referenced by this study and also in the alzhub library, so you can read them here.
Later studies that cite this one
1 study in the alzhub library lists this one in its references.
Related studies in Digital health tools from nearby years
Also tagged “machine”
834 studies in the library carry the topic tag “machine”; these are this study's neighbours in a fixed, alphabetical-by-hash tour of them, not the closest in content. All 834 tagged studies.